On multivariable analysis, nadir PSA >0.5 ng/mL was strongly associated with an increased likelihood of prostate cancer-specific mortality (HR: 25.70, 95% CI: 5.97-110.52, p < 0.001) and all-cause mortality (HR: 2.94, 95% CI: 1.76-4.91, p < 0.001). This evidence concerns the gene KLK3 and prostate carcinoma.